Demetrios K. Vassilatis

Athens, ESYE31 11527, Greece

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

BRF110, an Orally Active Nurr1-RXRα-Selective Rexinoid, Enhances BDNF Expression without Elevating Triglycerides.

BRF110, an Orally Active Nurr1-RXRα-Selective Rexinoid, Enhances BDNF Expression without Elevating Triglycerides.

Journal: Journal of medicinal chemistry

Published: February 13, 2025

Clinical differences between early-onset and mid-and-late-onset Parkinson's disease: Data analysis of the Hellenic Biobank of Parkinson's disease.

Clinical differences between early-onset and mid-and-late-onset Parkinson's disease: Data analysis of the Hellenic Biobank of Parkinson's disease.

Journal: Journal of the neurological sciences

Published: April 05, 2022

Functional Interaction Between α-Synuclein and Nurr1 in Dopaminergic Neurons.

Functional Interaction Between α-Synuclein and Nurr1 in Dopaminergic Neurons.

Journal: Neuroscience

Published: March 08, 2022

α-Synuclein Induces the GSK-3-Mediated Phosphorylation and Degradation of NURR1 and Loss of Dopaminergic Hallmarks.

α-Synuclein Induces the GSK-3-Mediated Phosphorylation and Degradation of NURR1 and Loss of Dopaminergic Hallmarks.

Journal: Molecular neurobiology

Published: August 03, 2021

Nurr1 repression mediates cardinal features of Parkinson's disease in α-synuclein transgenic mice.

Nurr1 repression mediates cardinal features of Parkinson's disease in α-synuclein transgenic mice.

Journal: Human molecular genetics

Published: March 04, 2021

The relationship between environmental factors and different Parkinson's disease subtypes in Greece: Data analysis of the Hellenic Biobank of Parkinson's disease.

The relationship between environmental factors and different Parkinson's disease subtypes in Greece: Data analysis of the Hellenic Biobank of Parkinson's disease.

Journal: Parkinsonism & related disorders

Published: March 03, 2019

Nurr1:RXRα heterodimer activation as monotherapy for Parkinson's disease.

Nurr1:RXRα heterodimer activation as monotherapy for Parkinson's disease.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: March 29, 2017

Structure-based virtual screening for drug discovery: principles, applications and recent advances.

Structure-based virtual screening for drug discovery: principles, applications and recent advances.

Journal: Current topics in medicinal chemistry

Published: August 27, 2013

Genetic assessment of familial and early-onset Parkinson's disease in a Greek population.

Genetic assessment of familial and early-onset Parkinson's disease in a Greek population.

Journal: European journal of neurology

Published: June 17, 2013

Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants.

Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants.

Journal: Neurobiology of aging

Published: April 09, 2013

Population-specific frequencies for LRRK2 susceptibility variants in the Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium.

Population-specific frequencies for LRRK2 susceptibility variants in the Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: August 20, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026